KR920000733A - 약학적활성 cns 화합물 - Google Patents
약학적활성 cns 화합물Info
- Publication number
- KR920000733A KR920000733A KR1019910009010A KR910009010A KR920000733A KR 920000733 A KR920000733 A KR 920000733A KR 1019910009010 A KR1019910009010 A KR 1019910009010A KR 910009010 A KR910009010 A KR 910009010A KR 920000733 A KR920000733 A KR 920000733A
- Authority
- KR
- South Korea
- Prior art keywords
- amino
- pyrimidine
- compound
- piperazinyl
- trichlorophenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 title claims 27
- -1 4-methyl-1-piperazinyl Chemical group 0.000 claims 17
- 239000001257 hydrogen Substances 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 125000005843 halogen group Chemical group 0.000 claims 5
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 4
- 125000006239 protecting group Chemical group 0.000 claims 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- OECYNAJTEARNMO-UHFFFAOYSA-N 2-(3,5-dimethylpiperazin-1-yl)-5-(2,3,5-trichlorophenyl)pyrimidin-4-amine Chemical compound C1C(C)NC(C)CN1C1=NC=C(C=2C(=C(Cl)C=C(Cl)C=2)Cl)C(N)=N1 OECYNAJTEARNMO-UHFFFAOYSA-N 0.000 claims 1
- RZABVGKFPFSKJP-UHFFFAOYSA-N 2-(4-benzylpiperazin-1-yl)-5-(2,3,5-trichlorophenyl)pyrimidin-4-amine Chemical compound NC1=NC(N2CCN(CC=3C=CC=CC=3)CC2)=NC=C1C1=CC(Cl)=CC(Cl)=C1Cl RZABVGKFPFSKJP-UHFFFAOYSA-N 0.000 claims 1
- VFQQXOLBMUZRLB-UHFFFAOYSA-N 2-(4-ethylpiperazin-1-yl)-5-(2,3,5-trichlorophenyl)pyrimidin-4-amine Chemical compound C1CN(CC)CCN1C1=NC=C(C=2C(=C(Cl)C=C(Cl)C=2)Cl)C(N)=N1 VFQQXOLBMUZRLB-UHFFFAOYSA-N 0.000 claims 1
- MQRADWWRHVBWHX-UHFFFAOYSA-N 2-(4-propylpiperazin-1-yl)-5-(2,3,5-trichlorophenyl)pyrimidin-4-amine Chemical compound C1CN(CCC)CCN1C1=NC=C(C=2C(=C(Cl)C=C(Cl)C=2)Cl)C(N)=N1 MQRADWWRHVBWHX-UHFFFAOYSA-N 0.000 claims 1
- XYMFQPCVHNYLAW-UHFFFAOYSA-N 2-n,2-n-diethyl-5-(2,3,5-trichlorophenyl)pyrimidine-2,4-diamine Chemical compound NC1=NC(N(CC)CC)=NC=C1C1=CC(Cl)=CC(Cl)=C1Cl XYMFQPCVHNYLAW-UHFFFAOYSA-N 0.000 claims 1
- 125000004362 3,4,5-trichlorophenyl group Chemical group [H]C1=C(Cl)C(Cl)=C(Cl)C([H])=C1* 0.000 claims 1
- XKIPLNIHBKSYNB-UHFFFAOYSA-N 5-(2,3,4,5-tetrachlorophenyl)pyrimidine-2,4-diamine Chemical compound NC1=NC(N)=NC=C1C1=CC(Cl)=C(Cl)C(Cl)=C1Cl XKIPLNIHBKSYNB-UHFFFAOYSA-N 0.000 claims 1
- NIKUMHWLORLHBZ-UHFFFAOYSA-N 5-(2,3-dichlorophenyl)-4-(4-methylpiperazin-1-yl)pyrimidin-2-amine Chemical compound C1CN(C)CCN1C1=NC(N)=NC=C1C1=CC=CC(Cl)=C1Cl NIKUMHWLORLHBZ-UHFFFAOYSA-N 0.000 claims 1
- TUQWAURGVMOVKD-UHFFFAOYSA-N 5-(3,5-dichlorophenyl)-2-(4-methylpiperazin-1-yl)pyrimidin-4-amine Chemical compound C1CN(C)CCN1C1=NC=C(C=2C=C(Cl)C=C(Cl)C=2)C(N)=N1 TUQWAURGVMOVKD-UHFFFAOYSA-N 0.000 claims 1
- KULFIMRKKQDMMW-UHFFFAOYSA-N 5-(3,5-dichlorophenyl)-6-(methoxymethyl)-2-(4-methylpiperazin-1-yl)pyrimidin-4-amine Chemical compound COCC1=NC(N2CCN(C)CC2)=NC(N)=C1C1=CC(Cl)=CC(Cl)=C1 KULFIMRKKQDMMW-UHFFFAOYSA-N 0.000 claims 1
- YJQWLFUYDVSUEX-UHFFFAOYSA-N 5-(3,5-dichlorophenyl)-6-(trifluoromethyl)pyrimidine-2,4-diamine Chemical compound FC(F)(F)C1=NC(N)=NC(N)=C1C1=CC(Cl)=CC(Cl)=C1 YJQWLFUYDVSUEX-UHFFFAOYSA-N 0.000 claims 1
- WJJDXHHPQMNMHX-UHFFFAOYSA-N 5-(4-amino-2,3,5-trichlorophenyl)pyrimidine-2,4-diamine Chemical compound NC1=NC(N)=NC=C1C1=CC(Cl)=C(N)C(Cl)=C1Cl WJJDXHHPQMNMHX-UHFFFAOYSA-N 0.000 claims 1
- NWAGOKSOHKBDPE-UHFFFAOYSA-N 5-(4-amino-3,5-dichlorophenyl)pyrimidine-2,4-diamine Chemical compound NC1=NC(N)=NC=C1C1=CC(Cl)=C(N)C(Cl)=C1 NWAGOKSOHKBDPE-UHFFFAOYSA-N 0.000 claims 1
- XEFKJVPJBULCGW-UHFFFAOYSA-N 6-methyl-5-(2,3,6-trichlorophenyl)pyrimidine-2,4-diamine Chemical compound CC1=NC(N)=NC(N)=C1C1=C(Cl)C=CC(Cl)=C1Cl XEFKJVPJBULCGW-UHFFFAOYSA-N 0.000 claims 1
- ASDHQAOMMACQGI-UHFFFAOYSA-N 6-methyl-5-(3,4,5-trichlorophenyl)pyrimidine-2,4-diamine Chemical compound CC1=NC(N)=NC(N)=C1C1=CC(Cl)=C(Cl)C(Cl)=C1 ASDHQAOMMACQGI-UHFFFAOYSA-N 0.000 claims 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000004849 alkoxymethyl group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 239000011630 iodine Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Liquid Crystal Substances (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Paper (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB909012316A GB9012316D0 (en) | 1990-06-01 | 1990-06-01 | Pharmacologically active cns compounds |
| GB9012316.7 | 1990-06-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR920000733A true KR920000733A (ko) | 1992-01-29 |
Family
ID=10676964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019910009010A Ceased KR920000733A (ko) | 1990-06-01 | 1991-05-31 | 약학적활성 cns 화합물 |
Country Status (25)
| Country | Link |
|---|---|
| EP (2) | EP0459819B1 (enExample) |
| JP (1) | JPH06340634A (enExample) |
| KR (1) | KR920000733A (enExample) |
| AT (1) | ATE141263T1 (enExample) |
| AU (2) | AU652753B2 (enExample) |
| CA (1) | CA2043640A1 (enExample) |
| CZ (1) | CZ281070B6 (enExample) |
| DE (1) | DE69121317T2 (enExample) |
| DK (1) | DK0459819T3 (enExample) |
| ES (1) | ES2093078T3 (enExample) |
| FI (1) | FI912623A7 (enExample) |
| GB (1) | GB9012316D0 (enExample) |
| GR (1) | GR3021237T3 (enExample) |
| HU (2) | HUT58707A (enExample) |
| IE (1) | IE911861A1 (enExample) |
| IL (2) | IL98330A (enExample) |
| MY (2) | MY136248A (enExample) |
| NO (1) | NO180375C (enExample) |
| NZ (3) | NZ248501A (enExample) |
| PL (2) | PL166656B1 (enExample) |
| PT (1) | PT97827B (enExample) |
| RU (1) | RU2091374C1 (enExample) |
| SK (1) | SK278444B6 (enExample) |
| TW (1) | TW224460B (enExample) |
| ZA (1) | ZA914165B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI895821A7 (fi) * | 1988-12-07 | 1990-06-08 | The Wellcome Foundation Ltd | Farmaseuttisesti aktivisia CNS-yhdisteitä |
| FI20021701L (fi) * | 1991-01-30 | 2002-09-24 | Wellcome Found | Veteen dispergoituvia tabletteja |
| US5629016A (en) * | 1991-01-30 | 1997-05-13 | Glaxo Wellcome Inc. | Water-dispersible tablets |
| GB9215908D0 (en) * | 1992-07-27 | 1992-09-09 | Wellcome Found | Water dispersible tablets |
| AU5704594A (en) * | 1992-12-18 | 1994-07-19 | Wellcome Foundation Limited, The | Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors |
| GB9226377D0 (en) * | 1992-12-18 | 1993-02-10 | Babbedge Rachel C | Pharmaceutical compositions |
| US5698226A (en) * | 1993-07-13 | 1997-12-16 | Glaxo Wellcome Inc. | Water-dispersible tablets |
| GB9319341D0 (en) * | 1993-09-17 | 1993-11-03 | Wellcome Found | Novel process |
| FR2741879A1 (fr) * | 1995-12-05 | 1997-06-06 | Esteve Labor Dr | Derives de fluorophenyl-triazines et pyrimidines, leur preparation et leur application en tant que medicament |
| US6440965B1 (en) * | 1997-10-15 | 2002-08-27 | Krenitsky Pharmaceuticals, Inc. | Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system |
| DE19751949A1 (de) * | 1997-11-24 | 1999-05-27 | Bayer Ag | Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration |
| GB9726987D0 (en) | 1997-12-22 | 1998-02-18 | Glaxo Group Ltd | Compounds |
| US6583148B1 (en) | 1999-04-08 | 2003-06-24 | Krenitsky Pharmaceuticals, Inc. | Neurotrophic substituted pyrimidines |
| DE19918325A1 (de) | 1999-04-22 | 2000-10-26 | Euro Celtique Sa | Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion |
| CA2383466C (en) | 1999-09-16 | 2009-08-25 | Tanabe Seiyaku Co., Ltd. | Aromatic nitrogen-containing 6-membered cyclic compounds |
| CN1438890A (zh) * | 2000-02-25 | 2003-08-27 | 弗·哈夫曼-拉罗切有限公司 | 腺苷受体调制剂 |
| US7273868B2 (en) | 2000-04-28 | 2007-09-25 | Tanabe Seiyaku Co., Ltd. | Pyrazine derivatives |
| AU2001241142B2 (en) | 2000-04-28 | 2005-09-22 | Tanabe Seiyaku Co., Ltd. | Cyclic compounds |
| JP5154728B2 (ja) * | 2000-07-24 | 2013-02-27 | クレニツキー・ファーマシューティカルズ，インコーポレイテッド | 神経栄養活性を有する置換５−アルキニルピリミジン |
| CN1503797A (zh) | 2001-02-26 | 2004-06-09 | 田边制药株式会社 | 吡啶并嘧啶或二氮杂萘衍生物 |
| CN1628109A (zh) * | 2002-02-05 | 2005-06-15 | 诺沃挪第克公司 | 新颖的芳基－与杂芳基－哌嗪 |
| TW200637556A (en) * | 2005-01-31 | 2006-11-01 | Basf Ag | Substituted 5-phenyl pyrimidines I in therapy |
| BRPI0613564A2 (pt) | 2005-07-04 | 2011-01-18 | Novo Nordisk As | compostos, seus usos na preparação de composições farmacêuticas e composições farmacêuticas compreendendo os mesmos |
| US8318927B2 (en) | 2006-05-23 | 2012-11-27 | High Point Pharmaceuticals, Llc | 6-(4-cyclopropylpiperazin-1-yl)-2′-methyl-[3, 4′]-bipyridine and its uses as a medicament |
| AU2007267197B2 (en) | 2006-05-29 | 2011-12-01 | High Point Pharmaceuticals, Llc | 3- (1, 3-Benzodioxol-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine H3 receptor antagonist |
| EP2014656A3 (en) | 2007-06-11 | 2011-08-24 | High Point Pharmaceuticals, LLC | New heteocyclic h3 antagonists |
| KR20180084153A (ko) | 2011-06-10 | 2018-07-24 | 메르크 파텐트 게엠베하 | Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물의 조성물 및 제조방법 |
| CN105899491B (zh) | 2014-01-17 | 2019-04-02 | 诺华股份有限公司 | 用于抑制shp2活性的1-哒嗪-/三嗪-3-基-哌(-嗪)/啶/吡咯烷衍生物及其组合物 |
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| WO2017216706A1 (en) | 2016-06-14 | 2017-12-21 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
| KR102571130B1 (ko) | 2017-01-10 | 2023-08-28 | 노파르티스 아게 | Alk 저해제 및 shp2 저해제를 포함하는 약제학적 조합 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE518622A (enExample) * | ||||
| FI895821A7 (fi) * | 1988-12-07 | 1990-06-08 | The Wellcome Foundation Ltd | Farmaseuttisesti aktivisia CNS-yhdisteitä |
| US5136080A (en) * | 1989-12-04 | 1992-08-04 | Burroughs Wellcome Co. | Nitrile compounds |
-
1990
- 1990-06-01 GB GB909012316A patent/GB9012316D0/en active Pending
-
1991
- 1991-05-30 ZA ZA914165A patent/ZA914165B/xx unknown
- 1991-05-31 CA CA002043640A patent/CA2043640A1/en not_active Abandoned
- 1991-05-31 JP JP3235334A patent/JPH06340634A/ja active Pending
- 1991-05-31 PL PL91290496A patent/PL166656B1/pl unknown
- 1991-05-31 NZ NZ248501A patent/NZ248501A/en unknown
- 1991-05-31 SK SK1643-91A patent/SK278444B6/sk unknown
- 1991-05-31 CZ CS911643A patent/CZ281070B6/cs unknown
- 1991-05-31 AT AT91304935T patent/ATE141263T1/de not_active IP Right Cessation
- 1991-05-31 TW TW080104285A patent/TW224460B/zh active
- 1991-05-31 RU SU914895583A patent/RU2091374C1/ru active
- 1991-05-31 EP EP91304935A patent/EP0459819B1/en not_active Expired - Lifetime
- 1991-05-31 NZ NZ238360A patent/NZ238360A/en unknown
- 1991-05-31 AU AU78097/91A patent/AU652753B2/en not_active Ceased
- 1991-05-31 IE IE186191A patent/IE911861A1/en unknown
- 1991-05-31 NZ NZ272001A patent/NZ272001A/en unknown
- 1991-05-31 DE DE69121317T patent/DE69121317T2/de not_active Expired - Fee Related
- 1991-05-31 PT PT97827A patent/PT97827B/pt not_active IP Right Cessation
- 1991-05-31 DK DK91304935.9T patent/DK0459819T3/da active
- 1991-05-31 PL PL91305331A patent/PL170373B1/pl unknown
- 1991-05-31 IL IL9833091A patent/IL98330A/en active IP Right Grant
- 1991-05-31 ES ES91304935T patent/ES2093078T3/es not_active Expired - Lifetime
- 1991-05-31 MY MYPI95001459A patent/MY136248A/en unknown
- 1991-05-31 NO NO912100A patent/NO180375C/no unknown
- 1991-05-31 FI FI912623A patent/FI912623A7/fi not_active Application Discontinuation
- 1991-05-31 IL IL113599A patent/IL113599A/xx not_active IP Right Cessation
- 1991-05-31 HU HU911826A patent/HUT58707A/hu unknown
- 1991-05-31 KR KR1019910009010A patent/KR920000733A/ko not_active Ceased
- 1991-05-31 EP EP95111314A patent/EP0679645A1/en not_active Withdrawn
- 1991-05-31 MY MYPI91000962A patent/MY109958A/en unknown
-
1994
- 1994-07-13 AU AU67455/94A patent/AU680252B2/en not_active Expired - Fee Related
-
1995
- 1995-06-30 HU HU95P/P00669P patent/HU211649A9/hu unknown
-
1996
- 1996-10-03 GR GR960402585T patent/GR3021237T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR920000733A (ko) | 약학적활성 cns 화합물 | |
| ATE230729T1 (de) | Benzamid-derivate und ihre verwendung als vasopressin-antagonisten | |
| HUP9902340A2 (hu) | Kondenzált piridinek és pirimidinek aril-amino-származékai, eljárás előállításukra, valamint e vegyületeket tartalmazó gyógyászati készítmények, továbbá e vegyületek alkalmazása | |
| ATE145208T1 (de) | Kondensierte thiophenverbindungen und deren verwendung | |
| DE69112061D1 (de) | Bis-benzo oder Benzopyrido-cyclohepta piperiden-piperidyliden, piperazinderivate als PAF Antagonisten, und Zusammensetzungen. | |
| TW372233B (en) | Compounds with a sulphamoyl and amidino group, process for preparing them and pharmaceutical compositions containing them | |
| ATE216584T1 (de) | Xanthine-derivate als antidepressiva | |
| KR920002555A (ko) | 앤지오텐신 ii 수용체 길항질인 신규한 피리미딘 유도체, 그 제조방법 및 그를 포함하는 제약학적 조성물 | |
| HUT54667A (en) | Process for producing alkyl-substituted piperazine derivatives and pharmaceutical compositions containing them | |
| ES8307760A1 (es) | Un procedimiento para la preparacion de derivados de 4-anilino-pirimidina. | |
| ES8200011A1 (es) | Procedimiento de preparacion de una composicion farmaceuticaen particular psicotropa. | |
| KR900015738A (ko) | 안압 강하제 | |
| IE862630L (en) | 3-VINYL AND 3-ETHYNYL-ß-CARBOLINES | |
| ATE172454T1 (de) | Pyridazinon derivate mit pharmazeutischer wirkung | |
| BG101601A (bg) | Фармацевтични пиперазинови производни | |
| ATE12232T1 (de) | Trisubstituierte pyrimido(5,4-d)pyrimidine, ihre herstellung und diese enthaltende arzneimittel. | |
| ES8203354A1 (es) | Un procedimiento para la produccion de nuevos derivados heterociclicos,. | |
| CA1102324A (en) | Benzylpyrimidines, processes for their manufacture, and drugs containing the said compounds | |
| KR950701916A (ko) | 신규한 피페라지닐-비스(알킬아미노)피리미딘 유도체와 그것의 산부가염 및 그들의 제조방법 | |
| US3657243A (en) | Pyridazone compounds and process for their production | |
| KR970021067A (ko) | 1-아지닐-테트라졸리논 | |
| US3553198A (en) | 2,4,6-substituted-5-arylsulfonyl-pyrimidines | |
| IE821938L (en) | Triazolobenzazepines | |
| ATE178330T1 (de) | Gefässverengende subtituierte dihydropyranopyridine | |
| RU95115681A (ru) | Пиримидиновые соединения, их кислые аддитивные соли, способ их получения и фармакомпозиция на их основе |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 19910531 |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 19960430 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 19910531 Comment text: Patent Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 19980924 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 19981130 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 19980924 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |